Entries by

RIFM Principle Scientist Gretchen Ritacco speaks about SenzaGen and RIFM collaboration

Here is an interview with Principal Scientist Gretchen Ritacco, MS, explaining why RIFM has focused some of its research on the potential for light to activate fragrance materials resulting in reactions in the body’s largest organ, the skin. Since June 2020, SenzaGen and the Research Institute for Fragrance Materials (RIFM) are collaborating to investigate in […]

The GARDpotency assay for potency-associated subclassification of chemical skin sensitizers – Rationale, method development and ring trial results of predictive performance and reproducibility

Toxicological Sciences, kfaa068, https://doi.org/10.1093/toxsci/kfaa068 Robin Gradin, Angelica Johansson, Andy Forreryd, Emil Aaltonen, Anders Jerre, Olivia Larne, Ulrika Mattson, Henrik Johansson Abstract Proactive identification and characterization of hazards attributable to chemicals are central aspects of risk assessments. Current legislations and trends in predictive toxicology advocate a transition from in vivo methods to non-animal alternatives. For skin sensitization assessment, […]

Our lab is open – rely on us for prompt and accurate results

SenzaGen has received questions from customers and partners about how COVID-19 has affected our daily operations. We continue to monitor the development of the COVID-19 epidemic closely and recognize that this situation represents an unprecedented challenge to the daily lives of our communities across the globe. To date, we continue to offer our full range […]

Web-based conference on “difficult-to-test” substances and regulatory testing

Join SenzaGen’s web-based conference on “Difficult-to-test” substances and regulatory testing in place of our exhibitor hosted session at SOT 2020 Take this chance and participate in our web-based conference on the latest news about GARD™ and how customers use the assays for skin and respiratory sensitization testing. Key takeaways Insights on sensitization assessment of “difficult-to-test” […]

SenzaGen’s operation during COVID-19

SenzaGen has received questions from customers and partners about how COVID-19 has affected our daily operations. We continue to monitor the development of the COVID-19 epidemic closely and recognize that this situation represents an unprecedented challenge to the daily lives of our communities across the globe. SenzaGen acts in adherence with the authorities’ guidelines in […]

Inter-laboratory ring trial of the GARD™air assay for assessment of respiratory sensitizers

Andy Forreryd1, Joshua Schmidt1, Robin Gradin1, Florence Burleson, Helge Gehrke3, Henrik Johansson1. 1SenzaGen AB, Lund, Sweden. 2Burleson Research Technologies, Morrisville, NC, USA. 3Eurofins BioPharma Product Testing Munich GmbH, Planegg, Germany. Sensitization of the respiratory tract by sensitizing chemicals may lead to severe bronchoconstriction and asthma-like symptoms with a potentially fatal outcome. However, proactive identification and […]